Background: Transforming growth factor beta 1 (TGFb1) is a pleiotropic cytokine that contributes to reparative skeletal remodeling by inducing osteoblast proliferation, migration, and angiogenesis. Organic bone matrix is the largest bodily reservoir for latent TGFb1, and active osteoblasts express cognate receptors for TGFb1 (TGFbRI and TGFbRII). During malignant osteolysis, TGFb1 is liberated from eroded bone matrix and promotes local progression of osteotropic solid tumors by its mitogenic and prosurvival activities.
T ransforming growth factor beta (TGFb) is a pleiotropic cytokine expressed in a variety of tissues. Three distinct TGFb isoforms (TGFb1, b2, or b3) have been identified, and exert their activities through receptor serine-threonine kinases.
1,2 Secreted as latent homodimer precursors, TGFb isoforms require catalysis by proteases, such as plasmin and matrix metalloproteinases, 3, 4 to be fully activated. 1, 5 Of the 3 isoforms, TGFb1 exists in highest concentrations in circulation, with platelets and bone matrix serving as the 2 largest biologic sources of TGFb1 within the body. 6, 7 Intracellular signaling mediated by TGFb requires the heterodimerization of its 2 cognate receptor serinethreonine kinases, TGFbRI and TGFbRII. 1, 2, 8 Biologic effects exerted by TGFb are mediated by 2 divergent signaling pathways, Smad-dependent (canonical) and Smad-independent (noncanonical). The canonical signaling pathway is well characterized and necessitates the phosphorylation and subsequent colocalization of Smad partnering complexes to the nucleus, which then serve as transcription factors for TGFb-mediated target genes. 1, 2, [8] [9] [10] The noncanonical pathway is less well defined, but this signaling pathway contributes to cell proliferation, motility, and survival by activation of the mitogen-activated protein kinase, Rho GTPase, and PI3K/AKT pathways, respectively. 9, 10 Physiologic activities of TGFb include regulation of skeletal health and remodeling. Normally, osteoblasts actively secrete TGFb1, which becomes incorporated into the hydroxyapatite matrix of bone, and is subsequently released into the local microenvironment and systemic circulation after osteoclast-mediated bone resorption. [11] [12] [13] During reparative or pathologic bone remodeling, TGFb1 concentrations transiently increase as a result of excessive osteoclast activity and consequent release of bone-derived TGFb1. 14, 15 Within regions of reparative skeletal healing, released TGFb1 can promote osteoblast precursor recruitment and motility, osteoblast proliferation and differentiation, as well as osteoblast survival. [16] [17] [18] [19] Upon completion of bone healing and attenuated osteoclastic activities, the release and pro-osteoblastic activities of TGFb1 become self-limiting.
Canine osteosarcoma (OS) is the most common primary bone tumor in dogs. 20 Clinically, affected dogs initially present for severe bone pain as a consequence of aggressive focal malignant osteolysis. [21] [22] [23] If localized pain is adequately controlled with interventional therapies, the majority of affected dogs eventually will develop distant metastatic disease. [24] [25] [26] [27] Osteosarcoma progression within bone or distant organs can be rationally attributed to the unchecked growth of malignant osteoblasts, and although conventional therapies, including limb amputation and systemic chemotherapy, improve overall survival times of affected dogs, there remains a clinical need for biologically driven discovery of novel therapeutic targets.
In the context of canine OS, inhibiting cellular pathways involved in osteoblast proliferation, migration, and survival might lead to therapeutic improvements. Given the pivotal role of TGFb1 in reparative bone biology, in conjunction with TGFb1's participation in diverse tumorigenic processes including growth, migration, and angiogenesis, [28] [29] [30] we sought to investigate the potential role of this signaling axis in canine OS. The specific aims of this study were (1) to characterize TGFb-associated ligand/receptor expressions in OS cell lines, spontaneous tumor samples, and OS-bearing dogs; (2) to study the in vitro effects of TGFb signaling blockade on malignant osteoblast proliferation, migration, survival, and vascular endothelial growth factor (VEGF) secretion; and (3) to evaluate the contribution of malignant osteolysis to circulating TGFb1 concentrations in dogs diagnosed with OS.
Materials and Methods

Cell Lines
Five canine (POS, HMPOS, COS31, Abrams, and D17) OS cell lines, 1 human (143B) OS cell line, 1 normal canine osteoblast cell line (K9OB), and a human pulmonary carcinoma cell line (A549) were used in this study. The POS and HMPOS cell lines were provided by James Farese, University of Florida, and the COS31 line was provided by Ahmed Shoieb, University of Tennessee. The K9OB cell line was established from a fragment of normal canine trabecular bone at the University of Illinois, Comparative Oncology Research Laboratory. All other cell lines were purchased commercially from American Tissue Culture Collection (Manassas, VA). All cell lines were cultured in either RPMI1640 or DMEM, with 10% fetal bovine serum and 1% penicillin/streptomycin. Cell cultures were maintained at 37°C in 5% CO 2 and passaged twice weekly. e Although the majority of antibodies utilized were validated for use in dogs based upon manufacturer specifications, specifically for TGFbRI and TGFbRII antibodies, canine crossreactivity for western blot analysis and immunohistochemistry was supported by the detection of proteins of expected molecular weight and subcellular localization, respectively, in conjunction with the use of known human positive controls.
Reagents and Antibodies
Western Blot Analysis
Protein Extraction and Loading Methodologies. For protein extraction, cell lines were grown to confluence in 100 mm petri dishes, and then scraped, harvested, and pelleted by centrifugation. Subsequently, proteins were extracted using a commercial reagent (M-PER Assay g ), mixed with a protease inhibitor cocktail, h and concentrations quantified using a commercial kit (BCA Assay g ). For all western blots conducted, 50 lg of protein was loaded and separated by SDS-PAGE using 10% polyacrylamide gels and transferred onto nitrocellulose membranes, with blocking at room temperature in 5% nonfat dry milk TBS-Tween immediately before incubation with target primary antibodies in 5% nonfat dry milk TBS-Tween overnight at 4°C; and after primary antibody incubation, membranes were washed and incubated for 1 hour with appropriate horseradish peroxidaseconjugated secondary antibodies (1 : 1,000) in 5% nonfat dry milk TBS-Tween and developed using a standard chemiluminescence detection kit. TGFbRI/II. Protein from 8 cell lines (5 canine OS, 1 normal canine osteoblast, 1 human OS, and 1 human lung carcinoma) was extracted and loaded as described. Membranes were incubated with either antihuman TGFbRI or TGFbRII antibodies (1:1000) in 5% nonfat dry milk TBS-Tween overnight at 4°C. Smad 2/3 and Phosphorylated-Smad 2. The HMPOS cell line was grown to 80% confluence, and then serum starved with or without inclusion of LY2109761 for 24 hours. Protein was collected from 5 experimental conditions, including (1) serum starved for 24 hours only or serum starved for 24 hours and then stimulated for 1 hour with (2) 10% FBS media only; (3) 10% FBS media + human recombinant TGFb1 (5 ng/mL); (4) 10% FBS media + LY2109761 (5 lM); and (5) 10% FBS media + human recombinant TGFb1 (5 ng/mL) + LY2109761 (5 lM). Membranes were incubated with either antihuman Smad 2/3 antibody (1 : 500) or antihuman phosphorylated-Smad 2 antibody (1 : 1,000) in 5% nonfat dry milk TBS-Tween overnight at 4°C.
Akt and Phosphorylated Akt. The HMPOS cell line was grown in complete media and then serum starved with or without inclusion of LY2109761 for 24 hours. Protein was collected from four experimental conditions, including (1) serum starved for 24 hours only or serum starved for 24 hours and then stimulated for 1 hour with (2) human recombinant TGFb1 (5 ng/mL); (3) LY2109761 (5 lM) alone; (4) LY2109761 (5 lM) + human recombinant TGFb1 (5 ng/mL). Membranes were incubated with either a rabbit polyclonal antimouse phosphorylated-Akt antibody or a rabbit polyclonal antimouse Akt antibody, both at a 1 : 1,000 dilution.
HIF-1a and b-actin. The Abrams cell line was grown in complete media to confluence and then exposed to LY2109761 (5 lM) for varying exposure durations. Membranes were incubated with a mouse monoclonal antihuman HIF-1a antibody (1 : 500). Subsequently, membranes were stripped and reprobed with a rabbit polyclonal antihuman b-actin antibody (1 : 5,000) and HRP-conjugated antirabbit secondary antibody (1 : 1,000). Quantitative dosimetry of HIF-1a relative to b-actin was performed using Image J software and expressed as a ratio.
Immunohistochemistry
Antibody Validation using Cell Pellets. Five canine OS cell lines and a human positive control cell line, A549, 31 were used to validate the application of TGFbRI/II antibodies for immunohistochemical staining of formalin-fixed paraffin-embedded samples. Adherent cell cultures were collected and washed in PBS, then pelleted by centrifugation. Each pellet was resuspended in 1 mL 10% formalin for 1 hour. Formalin was removed and cell pellets were resuspended uniformly into 1 mL 4% melted agarose gel by vortexing, and then immediately centrifuged to create an agarose-embedded cell pellet. Cell pellets then were trimmed and processed by an identical protocol routinely used for formalin-fixed paraffin-embedded tissue biopsy specimens. Briefly, paraffin-embedded cell pellets were sectioned every 3 lm and placed on positively charged slides, and dried for 1 hour at 60°C. Slides were deparaffinized with 3 sequential xylene washes, and subsequently hydrated using 100, 95, and 70% ethanol for 2 minutes each; followed by a water rinse. Slides were placed in 3% hydrogen peroxide in methanol for 15 minutes, and then treated with citrate buffer (pH 6.0) at a temperature of 95°C for 10 minutes. SuperSensitive Wash Buffer and Peroxide block was applied for 10 minutes at room temperature to block nonspecific staining. The rabbit polyclonal antihuman TGFbRI and TGFbRII antibodies were used at a concentration of 1 : 100 for 1 hour at room temperature. Slides were rinsed with SuperSensitive Wash Buffer and treated with Super Enhancer for 20 minutes at room temperature, and subsequently treated with Polymer-HRP for 30 minutes at room temperature and incubated with 3,3 0 -diaminobenzidine (DAB) at room temperature for 5 minutes. Slides were washed with SuperSensitive Wash Buffer and counterstained with Mayer's hematoxylin for 1 minute. Staining intensity for each canine OS cell line was qualitatively compared with the staining intensity of the human positive control using an arbitrary subjective integer scale: (À) no staining; (+) light uniform staining; (++) moderate uniform staining; and (+++) intense uniform staining.
Spontaneous OS Samples. Ten canine appendicular OS tissue blocks were provided by Dr. Luke Borst for immunohistochemical assessment. Slides were deparaffinized in xylene and rehydrated in ethanol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 15 minutes, and then slides were rinsed twice with wash buffer for 5 minutes. Slides were incubated with preheated 0.1% protease at 37°C for 20 minutes, and then rinsed in wash buffer for 2 minutes. Nonspecific staining was minimized by blocking for 10 minutes with Power Block, and then blocking for 15 minutes with avidin and biotin block. Blocked slides were incubated with rabbit polyclonal antihuman TGFbRI and TGFbRII antibodies at a concentration of 1 : 100 for 1 hour at room temperature. Slides were incubated with a biotinylated secondary antibody for 20 minutes at room temperature; then washed in buffer before incubation for 20 minutes with a streptavidin-biotinylated horseradish peroxidase complex, and developed with DAB substrate for 5 minutes and counterstained with hematoxylin. The negative control for the samples was processed identically in the absence of the primary antibody.
Colony-Forming Assay
The Abrams and HMPOS cell lines were seeded overnight into 6-well plates at a concentration of 50 cells per 3 mL of DMEM with 10% FBS. Upon adherence of individual cells, media was discarded and new media containing different experimental conditions was added, including DMEM 5% FBS only or DMEM 5% FBS with vehicle (DMSO) or a range of LY2109761 concentrations (0.3-5 lM). Cells were allowed to grow undisturbed for 7 (Abrams) or 10 (HMPOS) days. Subsequently, wells containing colonies were gently rinsed with chilled PBS, treated with 3 mL of solution containing 6.0% glutaraldehyde and 0.5% crystal violet for 30 minutes, and then rinsed with tap water. The number of visible colonies and the average size of colonies per experimental condition were quantified using imaging software.
j Two independent experiments were performed, with duplicates conducted for each experimental condition.
Scratch Assay
The Abrams, D17, and HMPOS cell lines were grown to 80% confluence in 6-well plates in DMEM supplemented with 10% FBS (complete media). Six experimental conditions for a duration of 48 hours were evaluated, including complete media only or complete media with vehicle (DMSO) or a range of LY2109761 concentrations (0.3-5 lM). A standardized acellular gap was created through cell monolayers using a 200-lL pipette tip in the middle of each well. Images of the acellular gap were captured at time 0 (maximal gap) and 48 hours for each experimental condition and analyzed with imaging software.
j The average width of 5 representative acellular gaps per experimental condition and cell line was used for quantitative comparisons at 48 hours, and 3 independent experimental replicates were performed.
VEGF ELISA
The Abrams, D17, and HMPOS cell lines were plated in complete media at 37°C and 5% CO 2 with a seeding density of 5,000 cells per well in a 96-well plate. After adherence, complete media was removed and replaced with 1% FBS DMEM with either vehicle (DMSO) or various concentrations of LY2109761 (0.3-5 lM) for 48 hours. Cell culture supernatants were collected and the concentration of secreted VEGF was quantified using a commercial kit (Canine VEGF Quantikine ELISA Kit a ) and normalized for cell proliferation by use of a colorimetric proliferation assay.
k Three independent experiments were performed, with hexaplicates conducted for each experimental condition.
TGFb1 ELISA
The Abrams, D17, and HMPOS cell lines were incubated with 1% FBS DMEM at different cell densities ranging from 25 to 100 9 10 3 cells per well for 24 hours. Cell culture supernatants were collected and total TGFb1 was determined with a commercially available ELISA kit (Quantikine â Mouse/Rat/Porcine/ Canine TGFb1 Assay a ). In 33 dogs with appendicular OS, heparinized plasma was collected pretreatment and 28 days after institution of standardized palliative radiation treatment and IV zoledronate. Plasma samples were stored at À80°C and batch analyzed using a commercially available ELISA kit (Quantikine Urine N-Telopeptide (NTx) assay Pretreatment morning urine was collected from 33 dogs treated with standardized radiation therapy and IV zoledronate. Urine samples were immediately centrifuged at 4°C at 250 9 g for 10 minutes, and the supernatant was collected and stored at À20°C before analysis was performed. Urine creatinine and NTx concentrations were measured with commercial ELISA test kits (Parameter Creatinine ELISA a ).
l
Statistical Analysis
Data sets were assessed for normality using the Shapiro-Wilk test. For all data comparisons evaluating the effect of TGFbRI/ II kinase blockade with LY2109761, a 1-ANOVA and posthoc Dunnet's test were used to identify significant differences among experimental conditions compared with DMSO vehicle control. In dogs with OS, Pearson correlation coefficient was used to characterize any relationship between pretreatment plasma TGFb1 and urine N-telopeptide concentrations and a 2-sided, paired t-test was utilized to determine the significance of changes in plasma TGFb1 concentrations before and after treatment with standardized radiation therapy and IV zoledronate. Significance was defined as P < .05.
Results
TGFbRI/II Expression and TGFb1 Secretion by OS Cell Lines
By western blot analysis, OS cells derived from human and canine origin demonstrated the presence of both TGFbRI and TGFbRII (Fig 1A) . Subjectively, TGFbRI was more robustly detectable in comparison with TGFbRII after normalizing for b-actin loading control. As expected based upon the participatory role of TGFb in homeostatic skeletal biology, normal canine osteoblasts also expressed TGFbRI and TGFbRII. Expression of TGFbRI and TGFbRII also was identified in OS cell lines by immunohistochemistry (Fig 1B) , demonstrating a membranous and cytosolic staining pattern consistent with the cellular localization of receptor serine-threonine kinases. Active secretion of the cognate ligand, TGFb1, was demonstrated by titration studies in three canine OS cell lines (Fig 1C) . At the highest cell densities evaluated (approximately 10 5 cells), total TGFb1 concentrations achieved physiologically relevant and active concentrations in the ng/mL range. The HMPOS cell line demonstrated the greatest capacity to secrete TGFb1, approximately doubling or quadrupling the concentrations liberated by Abrams and D17, respectively.
LY2109761 Blocks Canonical TGFb Signaling in Canine OS Cells
To confirm the capacity of LY2109761 to block the canonical signaling pathway of TGFb in malignant canine osteoblasts, HMPOS cells were exposed to 5 different in vitro conditions with subsequent characterization of phosphorylated-Smad 2 and Smad 2/3 by western blot analysis (Fig 2) . Under serum starved conditions only, the HMPOS cell line demonstrated detectable, but low, concentrations of phosphorylatedSmad 2. Stimulation for 1 hour with 10% FBS increased phosphorylated-Smad 2 concentrations, whereas combined stimulation with 10% FBS and recombinant TGFb1 markedly induced Smad 2 phosphorylation. The addition of 5 lM LY2109761 completely blocked 10% FBS-elicited Smad 2 phosphorylation, and substantially attenuated Smad 2 phosphorylation induced by concurrent stimulation with 10% FBS and recombinant TGFb1.
LY2109761 Attenuates Pro-tumorigenic Activities in
Canine OS Cells
Given the participatory role of TGFb signaling in multiple facets of cancer progression, the potential anticancer effects of LY2109761, a highly potent and selective small molecule inhibitor of TGFbRI (K i 0.04 lM) and TGFbRII (K i 0.3 lM), on canine OS (Fig 3A,B) , P < .01 for all comparisons. The average numbers of colonies formed after incubation with LY2109761 at each respective concentration were 204 AE 2 (0.3 lM), 200 AE 3 (1 lM), 139 AE 2 (3 lM), and 65 AE 1 (5 lM). A similar, but less substantial, reduction in cell proliferation was elicited by LY2109761 in the Abrams cell line (Fig 3C) . The average numbers of colonies formed for each experimental condition were 503 AE 7 (DMSO), 483 AE 5 (0.3 lM), 460 AE 42 (1 lM), 392 AE 4 (3 lM), and 344 AE 5 (5 lM). Paralleling the observed reduction in absolute number of colonies formed, higher concentrations of LY2109761 also modestly diminished the maximal diameter of cell colonies formed (Fig S1) . In addition to cell proliferation, the migration of malignant osteoblasts was attenuated by blocking TGFb signaling. The extent of migratory inhibition, however, was highly cell lineage-dependent, represented in order of greatest to least inhibited being D17, HMPOS, and Abrams. The migration of the D17 cell line was most robustly inhibited by LY2109761 at all concentrations tested (Fig 4A,B (Fig 4C) . The effect of LY2109761 on Abram cell migration was marginal, and even the 2 highest concentrations of 3 lM and 5 lM Given the pro-angiogenic properties of TGFb signaling, the effect of LY2109761 on VEGF secretion by D17, HMPOS, and Abrams cell lines was studied. Consistently, LY2109761 exerted a dose-dependent reduction in normalized secreted VEGF, generally at concentrations exceeding 1 lM (Fig 5A) . At the highest concentration of LY2109761, the secretion of VEGF was decreased by 40-45% in comparison with DMSO control for all cell lines tested. Canonical signaling through the TGFb pathway increases hypoxiainducible factor 1-alpha (HIF-1a) protein stability by downregulation of HIF-1a-associated prolyl hydroxylase (PHD), a key enzyme involved in targeting HIF1a for proteasome degradation. To provide a plausible mechanism for the observed reductions in secreted VEGF after exposure to LY2109761, a relationship between TGFb signaling inhibition and decreased HIF-1a protein stability was investigated. The Abrams OS cell line, which demonstrated the greatest reduction in secreted VEGF after LY2109761 exposure, was grown to confluence, serum starved overnight, and then incubated with 5 lM LY2109761 for different exposure durations (0-60 minutes). In comparison with untreated cells (time 0 minutes), HIF-1a concentrations decreased as a function of exposure time to LY2109761 with maximal reductions in HIF-1a approaching 35% after 60 minutes (Fig 5B,C) . Relative reductions in HIF-1a protein were mediated by LY2109761 and were not simply a by-product of DMSO exposure, because vehicle control experiments did not result in any change in HIF-1a protein as a function of exposure time (data not shown).
TGFb Axis in Dogs with OS
To expand upon the potential clinical relevance of the TGFb signaling axis in dogs with OS, the expression of TGFbRI and TGFbRII was investigated in 10 primary canine osteoblastic OS samples. Similar to canine OS cell lines, malignant osteoblasts in all tumor samples consistently stained positive for TGFbRI and TGFbRII (Fig 6A) . Given the focal malignant osteolytic nature of canine OS, in conjunction with bone matrix serving as the largest source of TGFb in the mammalian body, a correlation between pretreatment plasma TGFb1 concentration and urine N-telopeptide excretion was investigated in 33 dogs with appendicular OS. The average concentrations for urine N-telopeptide excretion and plasma TGFb1 were 191.1 AE 69.4 nM BCE/mM creatinine and 18.6 AE 8.7 ng/mL, respectively. Consistent with the notion that TGFb1 might be released into circulation as a consequence of focal malignant osteolysis, a positive correlation was identified between pretreatment plasma TGFb1 and urine N-telopeptide excretion ( Fig 6B) ; (r = 0.36; P = .04). To further substantiate that focal malignant osteolysis associated with OS might contribute to circulating TGFb1 concentrations, serial changes in TGFb1 concentrations were characterized in 33 OS-bearing dogs before and after institution of effective palliative treatment comprised of ionizing radiation and IV zoledronate. The average pretreatment plasma TGFb1 concentration of 18.6 AE 8.7 ng/mL was subsequently decreased to 13.8 AE 8.8 ng/mL after effective focal malignant osteolysis management (Fig 6C; P = . 001).
Discussion
The biologic functions of TGFb signaling actively participate in key cellular pathways, including apoptosis, cell cycle arrest, and immunity. [32] [33] [34] [35] In addition to normal physiologic processes, TGFb's canonical and noncanonical signaling pathways probably orchestrate various tumorigenic properties, including cancer cell proliferation, migration, survival, and angiogenesis. 1, 36 With respect to malignant bone pathology, TGFb has been identified as a key driver in perpetuating the successful development and progression of skeletal metastases, particularly for breast carcinoma. [37] [38] [39] In the context of skeletal metastases, carcinoma cells successfully reaching the fertile bone microenvironment will subvert and dysregulate osteoclastic activities, thereby promoting excessive bone resorption, and consequently facilitate the release of TGFb1 from the bone matrix. 40, 41 Serving as a potent mitogen for metastatic carcinoma cells, bone-derived TGFb1 promotes carcinoma progression and accelerates additional osteoclastic bone resorption, with the establishment of a paracrine feedback loop termed the "vicious cycle". 39 Although definitively a driver of skeletal metastases biology, the involvement of TGFb signaling for the establishment, maintenance, or progression of primary bone tumors, such as OS, remains incompletely investigated. Intuitively, given the role of TGFb in reparative bone biology in which Smad-dependent and -independent signaling are responsible for normal osteoblast migration, proliferation, and survival, 14, [42] [43] [44] it would be rational to speculate that TGFb signaling might also contribute to OS biology. Indeed, prior studies have investigated whether expression of different TGFb ligand isoforms in tumor samples might influence OS biologic behavior in human patients, [45] [46] [47] as well as if specific TGFb receptor gene polymorphisms might serve as risk factors for OS development. 48, 49 Extending upon studies that only characterized either ligand or receptor, more comprehensive investigations suggest cooperation between TGFb receptors and cognate ligands in the form of an autocrine feedback loop with the capacity to promote OS cell growth or drug resistance. [50] [51] [52] Complementing the results derived from studies of human and murine OS cells, the findings from the current investigation demonstrate that canine malignant osteoblasts similarly possess TGFb receptor/ligand signaling machinery. All canine cells of osteoblast lineage, normal and malignant, expressed both TGFbRI and TGFbRII, suggesting that TGFb signaling might not represent a malignant driver phenotype, but rather serve as a conserved pathway utilized by both reparative and malignant osteoblasts, alike. In addition, canine OS cells spontaneously secreted TGFb1 at low ng/ml concentrations, a systemic concentration of cytokine that is capable of exerting active biologic effects in vivo. 53 Based upon the coexpression of both receptor and cognate ligand, it is plausible that canine OS cells have the potential to exploit either autocrine or paracrine TGFb signaling as a mechanism favoring protumorigenesis.
Given the potential for the existence of an autocrine/paracrine signaling loop, in conjunction with the pivotal role that TGFb plays in cell cycle regulation and epithelial-mesenchymal transition (EMT), the current study explored the effects on canine OS cell proliferation and migration after exposure to LY2109761, a highly selective and potent small molecule inhibitor of TGFbRI and TGFbRII. The ability of LY2109761 to effectively block canonical TGFb-mediated signaling in canine OS cells was confirmed by the complete loss or substantial reduction in Smad 2 phosphorylation after stimulation with either 10% FBS alone or in conjunction with exogenous TGFb1, respectively. With regard to OS cell proliferation, a dose-dependent antimitogenic effect of LY2109761 was demonstrated in both the HMPOS and Abrams OS cell lines. Although maximal decreases in colony formation and size were observed at the highest concentration of LY2109761 (5 lM) and correlated well with attenuating Smad 2 phosphorylation, the antiproliferative activity of LY2109761 was operative at concentrations as low as 0.3 lM, a finding consistent with the reported inhibition constant (Ki) of LY2109761 for TGFbRII. 54 In addition to cell proliferation, TGFb signaling blockade with LY2109761 decreased canine OS cell migration. The extent of impaired migratory ability appeared cell line dependent, with the motility of D17 and Abrams OS cell lines being markedly and minimally attenuated, respectively. Given that the highest concentration of LY2109761 (5 lM) used in this study was expected to completely block canonical and noncanonical TGFb signaling, and yet the capacity of OS cells to migrate was not abolished completely, can be reconciled by alternate and redundant signaling pathways, such as c-Met, 55, 56 potentially exploited by canine OS for the preservation of cell motility.
Another pro-tumorigenic property investigated in this study was the influence of TGFb signaling on the secretion of VEGF by canine OS cells. As a proangiogenic cytokine, TGFb augments VEGF production by stabilizing HIF-1a indirectly by selectively inhibiting the transcription and translation of HIF-1a-associated prolyl hydroxylase (PHD), a negative regulator of HIF-1a stability. 57 Exposure to LY2109761 resulted in a dose-dependent decrease in secreted VEGF in all OS lines evaluated, with maximal VEGF reductions approaching 50%. Importantly, the postulated mechanism for the observed decreases in VEGF was supported by the documented decreases in HIF-1a, possibly through decreased stability, after exposure to LY2109761. Furthermore, the observed decreases in HIF-1a in close temporal relationship with LY2109761 exposure are not unexpected, given the rapid posttranslational regulation of HIF-1a by proteasome degradation, and consequent short HIF-1a half-life (<5 minutes). 58 The potential translational relevance of TGFb signaling in dogs diagnosed with OS initially was investigated by evaluation of TGFbRI and TGFbRII expression in 10 archived osteoblastic OS tissue samples. Consistent with the findings derived from immortalized canine OS cell lines, all 10 spontaneously arising OS samples demonstrated moderately strong and uniform positive staining for both receptors. Given that bone serves as the largest anatomic reservoir for TGFb1 in the body, in conjunction with the focally osteolytic nature of OS, a correlative relationship between plasma TGFb1 and urine N-telopeptide in 33 treatment-na€ ıve OS-bearing dogs was explored and found to be significant. In the same 33 dogs, to indirectly support the notion that not only focal malignant osteolysis but also viable OS cells might contribute to circulating plasma TGFb1 concentrations, serial plasma TGFb1 concentrations were compared in each dog before and after the institution of effective palliative treatment comprised of standardized ionizing radiation and IV zoledronate. Not unexpectedly, in the majority of dogs (24/33), plasma TGFb1 concentrations were substantially decreased after the institution of palliative treatment expected to decrease malignant osteolysis and induce OS cell apoptosis.
The collective findings of TGFbRI/II expression in OS samples and correlation between plasma TGFb1 and focal osteolysis in OS-bearing dogs support the possibility that TGFb signaling might contribute to OS progression, and hence blockade of TGFb-mediated effects could be a rational therapeutic strategy. Although prolonged or complete TGFb blockade would carry the risk for development of severe adverse effects, including lymphoproliferative disorders and exacerbation of orthopedic pathology such as osteoarthritis, several potential blocking strategies and dosing regimens appear to be viable for the management of fibrotic diseases and cancer. 59 Based upon a large body of preclinical efficacy studies, coupled with early promising results in Phase 1, 2, and 3 studies in which TGFb blocking strategies are being evaluated for the management of diverse cancers in people, further investigations are clinically warranted to explore the suitability of inhibiting TGFb signaling as an adjuvant treatment in dogs with OS.
Although the findings from this study provide incremental advances in the potential role of TGFb signaling in OS, there are several limitations in the current investigation that should be recognized. First, no direct evidence, in vitro or in vivo, was provided to support the existence of a TGFb-mediated autocrine/paracrine feedback loop in canine OS, and despite the demonstrated expression of cognate receptor/ligand pairs in OS cells, the biologic relevance of the identified cellular machinery cannot be ascertained. Second, although LY2109761 attenuated several pro-tumorigenic characteristics in vitro, the concentrations (5 lM) and exposure durations (24-48 hours) might not be biologically achievable or relevant in dogs with OS. However, preclinical murine models of skeletal metastases suggest that LY2109761 is tolerated and possesses favorable pharmacokinetics, as well as allowing for anticancer activities to be exerted within the bone microenvironment. 60, 61 Third, although LY2109761 decreased VEGF secretion in all canine OS cell lines tested, it cannot be concluded that this result is a direct consequence of decreased HIF-1a protein stability after TGFb signaling blockade or simply an experimental design epiphenomenon. Fourth, the contributory origins of plasma TGFb1 measured in OS-bearing dogs cannot be stated definitively. Nominal platelet aggregation, despite collection of blood in heparinized tubes, could have randomly influenced plasma TGFb1 concentrations. Last, the decreases in plasma TGFb1 after institution of ionizing radiation and IV zoledronate could not be strictly attributed to decreases in focal malignant osteolysis and OS cell viability, because whole skeletal antiresorptive effects of zoledronate would be anticipated to produce similar TGFb1 reductive tracing.
In conclusion, findings from this investigation are novel from the perspective of canine OS biology, and corroborate existing studies conducted in human and murine OS cell lines. Future pharmacokinetic and tolerability studies in dogs with TGFb blocking molecules, such as LY2109761, will be necessary to guide the formulation of appropriate dosing regimens. The generation of preliminary and interesting data in this report provides impetus to further evaluate the feasibility and suitability of TGFb blocking strategies for the management of canine OS. 
